Managers / Q4 2021 · view latest →
72 Investment Holdings, LLC
CIK 0001832749 · 72 CUMMINGS POINT ROAD, STAMFORD, CT, 06902 · 203-890-2000
Summary
72 Investment Holdings, LLC reported $113M in U.S.-listed holdings across 6 positions for Q4 2021.
The portfolio is heavily concentrated: Prometheus Biosciences alone accounts for 64.8% of reported value.
Compared with Q3 2021, the fund opened 2 new positions and exited 0.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Other · 85.9% · $97M
- Common Stock · 14.1% · $16M
Quarter-over-Quarter Changes full breakdown →
vs Q3 2021 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| TRDAENTRADA THERAPTEUTICS INC | NEW | +509.0K | 509.0K | +$9M | $9M |
| WEWORK INC | NEW | +30.0K | 30.0K | +$258,000 | $258,000 |
| PROMETHEUS BIOSCIENCES INC | HELD | +0 | 1.85M | +$29M | $73M |
| CRBUCARIBOU BIOSCIENCES INC | HELD | +0 | 474.1K | −$4M | $7M |
| OMEGA THERAPEUTICS INC | HELD | +0 | 352.9K | −$3M | $4M |
| PRAXIS PRECISION MEDICINES I | HELD | +0 | 989.0K | +$1M | $19M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q4 2021
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | PROMETHEUS BIOSCIENCES INC | COM | 64.85% | $73M | 1.85M |
| 2 | PRAXIS PRECISION MEDICINES I | COM | 17.29% | $19M | 989.0K |
| 3 | TRDAENTRADA THERAPTEUTICS INChistory → | COM | 7.73% | $9M | 509.0K |
| 4 | CRBUCARIBOU BIOSCIENCES INChistory → | COM | 6.35% | $7M | 474.1K |
| 5 | OMEGA THERAPEUTICS INC | COMMON STOCK | 3.55% | $4M | 352.9K |
| 6 | WEWORK INC | CL A | 0.23% | $258,000 | 30.0K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $50M | 5 | May 15, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $51M | 5 | Feb 17, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $68M | 5 | Nov 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $38M | 6 | Aug 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $36M | 6 | May 15, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $49M | 7 | Feb 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $47M | 7 | Nov 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $40M | 7 | Aug 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $67M | 7 | May 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $23M | 6 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $15M | 5 | Nov 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $13M | 4 | Aug 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $211M | 5 | May 15, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $218M | 5 | Feb 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $126M | 5 | Nov 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $65M | 5 | Aug 15, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $91M | 6 | May 16, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $113M | 6 | Feb 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $80M | 4 | Nov 15, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $63M | 2 | Aug 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $66M | 2 | May 17, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $742M | 2 | Feb 16, 2021 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.